Somatostatin analogues for the prevention of pancreatic fistula after open pancreatoduodenectomy: A nationwide analysis

B.T. Bootsma*, V.D. Plat, T. van de Brug, D.E. Huisman, M. Botti, P.B. van den Boezem, B.A. Bonsing, K. Bosscha, C.H.C. Dejong, B. Groot-Koerkamp, J. Hagendoorn, E. van der Harst, I.H. de Hingh, V.E. de Meijer, M.D. Luyer, V.B. Nieuwenhuijs, B.K. Pranger, H.C. van Santvoort, J.H. Wijsman, B.M. ZonderhuisG. Kazemier, M.G. Besselink, F. Daams, Dutch Pancreatic Canc Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Background: Somatostatin analogues (SA) are currently used to prevent postoperative pancreatic fistula (POPF) development. However, its use is controversial. This study investigated the effect of different SA protocols on the incidence of POPF after pancreatoduodenectomy in a nationwide population.Methods: All patients undergoing elective open pancreatoduodenectomy were included from the Dutch Pancreatic Cancer Audit (2014-2017). Patients were divided into six groups: no SA, octreotide, lanreotide, pasireotide, octreotide only in high-risk (HR) patients and lanreotide only in HR patients. Primary endpoint was POPF grade B/C. The updated alternative Fistula Risk Score was used to compare POPF rates across various risk scenarios.Results: 1992 patients were included. Overall POPF rate was 13.1%. Lanreotide (10.0%), octreotide-HR (9.4%) and no protocol (12.7%) POPF rates were lower compared to the other protocols (varying from 15.1 to 19.1%, p = 0.001) in crude analysis. Sub-analysis in patients with HR of POPF showed a significantly lower rate of POPF when treated with lanreotide (10.0%) compared to no protocol, octreotide and pasireotide protocol (21.6-26.9%, p = 0.006). Octreotide-HR and lanreotide-HR protocol POPF rates were comparable to lanreotide protocol, however not significantly different from the other protocols. Multi-variable regression analysis demonstrated lanreotide protocol to be positively associated with a low odds-ratio (OR) for POPF (OR 0.387, 95% CI 0.180-0.834, p = 0.015). In-hospital mortality rates were not affected.Conclusion: Use of lanreotide in all patients undergoing pancreatoduodenectomy has a potential protective effect on POPF development. Protocols for HR patients only might be favorable too. However, future studies are warranted to confirm these findings. (C) 2022 The Authors. Published by Elsevier B.V. on behalf of IAP and EPC.
Original languageEnglish
Pages (from-to)421-426
Number of pages6
Issue number3
Publication statusPublished - 1 Apr 2022


  • Somatostatin analogues
  • Postoperative Pancreatic Fistula
  • Pancreatoduodenectomy
  • Lanreotide
  • Pasireotide
  • Octreotide


Dive into the research topics of 'Somatostatin analogues for the prevention of pancreatic fistula after open pancreatoduodenectomy: A nationwide analysis'. Together they form a unique fingerprint.

Cite this